Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma

The aim of this longitudinal study was to assess the frequency of nonreversible airflow obstruction (NRAO) among adults with moderate to severe asthma, and to compare the decline of forced expiratory volume in one second (FEV1) in asthmatics with reversible and nonreversible airflow obstruction. Ninety-two (31 males) life-long nonsmokers with asthma participated in a 10-yr follow-up study; mean age 37 yrs (range 18-64) and duration of asthma 16 yrs (range 2-60) at enrolment. Case history, including use of asthma medication, was obtained, and pulmonary function, including diffusion capacity, was measured using standard techniques. At enrolment, all patients had typical symptoms and reversible airflow obstruction. (NRAO) was defined as FEV1 <80% predicted and change in deltaFEV1 after 5 mg salbutamol <9% pred. A total of 21 (23%) patients (mean age at enrolment 32 yrs) fulfilled the criteria for NRAO at the time of follow-up; current therapy was inhaled steroids (n=21, mean daily dose 1.5 mg), oral steroids (n=14), theophylline (n=20), oral beta2-agonist (n=6) and inhaled beta2-agonist. The patients with NRAO (n=21) had a steeper decline in FEV1 than the remaining patients (n=71, reversible airflow obstruction (RAO)), mean+/-SD 53+/-23 mL x yr(-1) and 36+/-21 mL x yr(-1), respectively (p<0.003). Increasing degree of bronchodilator reversibility (deltaFEV1% pred) at enrolment (p=0.002) and long-term treatment with oral corticosteroids (p=0.009) were associated with an increased risk for the presence of NRAO at follow-up. The comparison of data for NRAO and RAO patients (at follow-up) revealed no significant differences in mean values for total diffusion capacity (TL,CO), diffusion constant (KCO), or total lung capacity. The findings suggest that a subgroup of asthmatics may experience very steep rates of decline in forced expiratory volume in one second leading to severe nonreversible airflow obstruction, whereas no indication was found that long-standing asthma may lead to the development of emphysema.

This article has been cited by other articles:

				P. Shirtcliffe, M. Weatherall, and R. Beasley From the authors Eur. Respir. J., January 1, 2008; 31(1): 218 - 219. [Full Text] [PDF]

				D. M. Mannino and S. Braman The Epidemiology and Economics of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 502 - 506. [Abstract] [Full Text] [PDF]

				T. R. Bai, J. M. Vonk, D. S. Postma, and H. M. Boezen Severe exacerbations predict excess lung function decline in asthma Eur. Respir. J., September 1, 2007; 30(3): 452 - 456. [Abstract] [Full Text] [PDF]

				N. J. Brown, C. M. Salome, N. Berend, C. W. Thorpe, and G. G. King Airway Distensibility in Adults with Asthma and Healthy Adults, Measured by Forced Oscillation Technique Am. J. Respir. Crit. Care Med., July 15, 2007; 176(2): 129 - 137. [Abstract] [Full Text] [PDF]

				C. M. Lloyd and D. S. Robinson Allergen-induced airway remodelling Eur. Respir. J., May 1, 2007; 29(5): 1020 - 1032. [Abstract] [Full Text] [PDF]

				Y.-C. Wang, J.-M. Lin, C.-Y. Li, L.-T. Lee, Y.-L. Guo, and F.-C. Sung Prevalence and Risks of Chronic Airway Obstruction: A Population Cohort Study in Taiwan Chest, March 1, 2007; 131(3): 705 - 710. [Abstract] [Full Text] [PDF]

				D. M. Mannino, G. Watt, D. Hole, C. Gillis, C. Hart, A. McConnachie, G. Davey Smith, M. Upton, V. Hawthorne, D. D. Sin, et al. The natural history of chronic obstructive pulmonary disease. Eur. Respir. J., March 1, 2006; 27(3): 627 - 643. [Full Text] [PDF]

				P Lange, H Scharling, C S Ulrik, and J Vestbo Inhaled corticosteroids and decline of lung function in community residents with asthma Thorax, February 1, 2006; 61(2): 100 - 104. [Abstract] [Full Text] [PDF]

				P Ernst Inhaled corticosteroids moderate lung function decline in adults with asthma Thorax, February 1, 2006; 61(2): 93 - 94. [Full Text] [PDF]

				S. Zanconato, G. Meneghelli, R. Braga, F. Zacchello, E. Baraldi, and on behalf of the Working Group Office Spirometry in Primary Care Pediatrics: A Pilot Study Pediatrics, December 1, 2005; 116(6): e792 - e797. [Abstract] [Full Text] [PDF]

				E. L. J. van Rensen, J. K. Sont, C. E. Evertse, L. N. A. Willems, T. Mauad, P. S. Hiemstra, P. J. Sterk, and the AMPUL Study Group Bronchial CD8 Cell Infiltrate and Lung Function Decline in Asthma Am. J. Respir. Crit. Care Med., October 1, 2005; 172(7): 837 - 841. [Abstract] [Full Text] [PDF]

				A. L. James, L. J. Palmer, E. Kicic, P. S. Maxwell, S. E. Lagan, G. F. Ryan, and A. W. Musk Decline in Lung Function in the Busselton Health Study: The Effects of Asthma and Cigarette Smoking Am. J. Respir. Crit. Care Med., January 15, 2005; 171(2): 109 - 114. [Abstract] [Full Text] [PDF]

				B. T. Kitch, A. D. Paltiel, K. M. Kuntz, D. W. Dockery, J. P. Schouten, S. T. Weiss, and A. L. Fuhlbrigge A Single Measure of FEV1 Is Associated With Risk of Asthma Attacks in Long-term Follow-up Chest, December 1, 2004; 126(6): 1875 - 1882. [Abstract] [Full Text] [PDF]

				J. Elias The Relationship Between Asthma and COPD: Lessons From Transgenic Mice Chest, August 1, 2004; 126(2_suppl_1): 111S - 116S. [Abstract] [Full Text] [PDF]

				J. F. Donohue Therapeutic Responses in Asthma and COPD: Bronchodilators Chest, August 1, 2004; 126(2_suppl_1): 125S - 137S. [Abstract] [Full Text] [PDF]

				M. Gaga Fixed obstruction in severe asthma: not just a matter of time Eur. Respir. J., July 1, 2004; 24(1): 8 - 10. [Full Text] [PDF]

				G. E. Silva, D. L. Sherrill, S. Guerra, and R. A. Barbee Asthma as a Risk Factor for COPD in a Longitudinal Study Chest, July 1, 2004; 126(1): 59 - 65. [Abstract] [Full Text] [PDF]

				F.-Q. Wen, X. Liu, T. Kobayashi, S. Abe, Q. Fang, T. Kohyama, R. Ertl, Y. Terasaki, L. Manouilova, and S. I. Rennard Interferon-{gamma} Inhibits Transforming Growth Factor-{beta} Production in Human Airway Epithelial Cells by Targeting Smads Am. J. Respir. Cell Mol. Biol., June 1, 2004; 30(6): 816 - 822. [Abstract] [Full Text] [PDF]

				S. I. Rennard and S. G. Farmer Exacerbations and Progression of Disease in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2004; 1(2): 88 - 92. [Abstract] [Full Text] [PDF]

				J. D. Spahn, R. Cherniack, K. Paull, and E. W. Gelfand Is Forced Expiratory Volume in One Second the Best Measure of Severity in Childhood Asthma? Am. J. Respir. Crit. Care Med., April 1, 2004; 169(7): 784 - 786. [Full Text] [PDF]

				D. Tashkin and S. Kesten Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses Chest, May 1, 2003; 123(5): 1441 - 1449. [Abstract] [Full Text] [PDF]

				J M Vonk, H Jongepier, C I M Panhuysen, J P Schouten, E R Bleecker, and D S Postma Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up Thorax, April 1, 2003; 58(4): 322 - 327. [Abstract] [Full Text] [PDF]

				H Milgrom Is there a role for treatment of asthma with omalizumab? Arch. Dis. Child., January 1, 2003; 88(1): 71 - 74. [Abstract] [Full Text] [PDF]

				D. M. Mannino COPD* : Epidemiology, Prevalence, Morbidity and Mortality, and Disease Heterogeneity Chest, May 1, 2002; 121 (2009): 121S - 126S. [Abstract] [Full Text] [PDF]

				A. F. Gelb, J. Licuanan, C. M. Shinar, and N. Zamel Unsuspected Loss of Lung Elastic Recoil in Chronic Persistent Asthma Chest, March 1, 2002; 121(3): 715 - 721. [Abstract] [Full Text] [PDF]

				A. ten BRINKE, A. H. ZWINDERMAN, P. J. STERK, K. F. RABE, and E. H. BEL Factors Associated with Persistent Airflow Limitation in Severe Asthma Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 744 - 748. [Abstract] [Full Text] [PDF]

				A. F. GELB and N. ZAMEL Unsuspected Pseudophysiologic Emphysema in Chronic Persistent Asthma Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1778 - 1782. [Abstract] [Full Text]